Zevra Therapeutics, Inc.
ZVRAHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeZevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. With a market capitalization of $643.2M, it sits in small-cap territory. The company develops its products through Ligand Activated Technology platform.
Market Cap
$643.2M
Beta
0.88
P/E (TTM)
5.41
P/E (Fwd)
5.68
EPS (TTM)
$2.01
EPS (Fwd)
$1.92
ROE
100.6%
ROA
2.8%
Cash
$200.6M
Total Debt
$1.1M
Free CF
$25.9M
52W Change
21.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $200.6M in cash comfortably exceeding the $1.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $25.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 100.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $10.2M (2022) to $106.5M (2025), reflecting a 948% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing ZVRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.